David Gwilliam obtained a Bachelor of Science degree in Biochemistry & Genetics from the University of Nottingham, followed by a Master of Science degree in Cancer Immunotherapy from the same university. David’s research involved studies into the effect of cytokine signalling on naïve CD4+ T-cell activation.
Following completion of his studies in 2007, David worked in industry, for MedImmune UK Ltd, before joining AdamsonJones in July 2008. He trained with the firm and completed his qualification as both UK and European Patent Attorney in 2012. David is involved in all aspects of patent drafting and prosecution, predominantly in the areas of biotechnology and healthcare, and is also a key member of our Trade Marks team, having qualified as a Chartered Trade Mark Attorney in 2014.
David is a Fellow of the Chartered Institute of Patent Attorneys, and a member of the European Patents Institute.
For more information about David's practice, and representative clients, patents and trade marks click here.
CEO, UK medical devices company
In the competitive world of the biosciences, third party patent rights (TPRs) can stand in the way of a planned course of action, even after significant investment has been made. Knowledge of such rights and potential rights at an early stage is invaluable.
All the latest news and events straight to your inbox. Fill in your details below.